Abstract 1956P
Background
Alternative promoters and splice sites enable most human genes to generate multiple transcript isoforms, significantly increasing phenotypic complexity. Large-scale tumor RNA-seq analysis has demonstrated widespread splicing aberrations and alternative promoter activation in cancer, implicating isoform dysregulation as a crucial factor in carcinogenesis.
Methods
By integrating RNA-seq data from TCGA, PCAWG, and GTEx projects, we reconstructed individual transcript sequences expressed in more than 26000 cancer and normal samples, elucidating a comprehensive panorama of alternative isoform utilization across 39 tissues and 38 cancer types.
Results
Our isoform-centric analysis reveals that (1) global transcriptome architecture is distinct across tissues, between cancer and normal samples of the same tissue origin, and between cancer molecular subtypes—even at sub-gene resolution; (2) alternative promoter usage and splicing together contribute to ∼40% of transcriptome heterogeneity across tissues and 50-60% within tissues and cancer types; (3) cancer frequently increases the usage of aberrant tumor suppressor gene isoforms lacking protein-coding potential; (4) differentially used isoforms hold significant prognostic value in various cancers, with aberrant transcripts from NRG1, CAMTA1, and LRP1B demonstrating the strongest association with survival; and (5) co-occurring differential splicing events within single RNA molecules may offset each other's frame-shifting effects.
Conclusions
Our findings indicate cancer frequently dysregulates alternative isoform usage, perturbing key oncogenic pathways. This highlights the value of isoform-resolution transcriptome profiling for improved individualized cancer diagnostics and treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korea Advanced Institute of Science and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
252P - Evolution of breast cancer biological subtypes between pre-treatment biopsy and residual disease after neoadjuvant therapy
Presenter: Katarzyna Pogoda
Session: Poster session 13
253P - Single-cell RNA sequencing reveals tumor heterogeneity and potential mechanisms of response/resistance in breast cancer treated with neoadjuvant therapy
Presenter: Marcela Carausu
Session: Poster session 13
254P - IHC and GEX biomarkers and their prognostic and treatment predictive role in the neoadjuvant treatment of breast cancer
Presenter: Hani Saghir
Session: Poster session 13
255P - Predicting early recurrence in breast cancer patients undergoing neo-adjuvant chemotherapy through MRI-radiomics analysis
Presenter: Anna D'Angelo
Session: Poster session 13
256P - Protein signature of tertiary lymphoid structure predicts efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
Presenter: Shuling Zhou
Session: Poster session 13
257P - Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort
Presenter: Andrea Joaquin Garcia
Session: Poster session 13
258P - Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC)
Presenter: Coralia Bueno Muiño
Session: Poster session 13
1954P - 5-methylthioadenosine phosphorylase (MTAP) loss in clinically advanced uveal melanoma (CAUM): A comprehensive genomic profiling (CGP) study
Presenter: Nimisha Srivastava
Session: Poster session 13
1955P - Glycan-programmed T cell immunity: Effective adoptive T cell transfer in a CRC preclinical model
Presenter: Yong Miao
Session: Poster session 13